share_log

Intelligent Bio Solutions | S-3: Registration statement for specified transactions by certain issuers

Intelligent Bio Solutions | S-3:特定交易註冊聲明

美股sec公告 ·  03/04 17:32
Moomoo AI 已提取核心訊息
Intelligent Bio Solutions Inc. has filed a Form S-3 with the Securities and Exchange Commission (SEC) on March 4, 2024, to register shares for potential future sale. This registration statement pertains to the resale of up to 636,367 shares of common stock, which may be issued upon the exercise of certain Series G Warrants and Placement Agent Warrants. The Series G Warrants were issued to certain selling stockholders in exchange for their exercise of existing Series E Warrants, and the Placement Agent Warrants were issued to Ladenburg Thalmann & Co. Inc., the placement agent for the issuance of the Inducement Warrants. The company will not receive any proceeds from the sale of shares by the selling stockholders but will receive the exercise price if...Show More
Intelligent Bio Solutions Inc. has filed a Form S-3 with the Securities and Exchange Commission (SEC) on March 4, 2024, to register shares for potential future sale. This registration statement pertains to the resale of up to 636,367 shares of common stock, which may be issued upon the exercise of certain Series G Warrants and Placement Agent Warrants. The Series G Warrants were issued to certain selling stockholders in exchange for their exercise of existing Series E Warrants, and the Placement Agent Warrants were issued to Ladenburg Thalmann & Co. Inc., the placement agent for the issuance of the Inducement Warrants. The company will not receive any proceeds from the sale of shares by the selling stockholders but will receive the exercise price if the warrants are exercised for cash. The registration allows the selling stockholders to sell their shares from time to time in the public market, through private transactions, or otherwise, at prevailing market prices or at negotiated prices. Intelligent Bio Solutions Inc. has agreed to keep the prospectus effective until all registered shares are sold or the offering is otherwise completed. The company has also entered into indemnification agreements with its directors and officers, and its bylaws provide for indemnification to the fullest extent permitted by Delaware law.
Intelligent Bio Solutions Inc.已於2024年3月4日向美國證券交易委員會(SEC)提交了S-3表格,要求註冊股票以備將來可能出售。本註冊聲明涉及最多636,367股普通股的轉售,這些普通股可以在行使某些G系列認股權證和配售代理認股權證時發行。G系列認股權證是向某些出售股東發行的,以換取他們行使現有的E系列認股權證,配售代理認股權證是向拉登堡塔爾曼公司發行的。Inc.,發行激勵認股權證的配售代理。該公司不會從出售股東出售股票中獲得任何收益,但如果認股權證以現金行使,則將獲得行使價。註冊允許出售股東不時在公開市場上,通過私下交易或其他方式,以現行市場價格或協議價格出售其股票。Intelligent Bio Solutions Inc.已同意在出售所有註冊股票或以其他方式完成發行之前保持招股說明書的有效性。該公司還與其董事和高級管理人員簽訂了賠償協議,其章程規定在特拉華州法律允許的最大範圍內進行賠償。
Intelligent Bio Solutions Inc.已於2024年3月4日向美國證券交易委員會(SEC)提交了S-3表格,要求註冊股票以備將來可能出售。本註冊聲明涉及最多636,367股普通股的轉售,這些普通股可以在行使某些G系列認股權證和配售代理認股權證時發行。G系列認股權證是向某些出售股東發行的,以換取他們行使現有的E系列認股權證,配售代理認股權證是向拉登堡塔爾曼公司發行的。Inc.,發行激勵認股權證的配售代理。該公司不會從出售股東出售股票中獲得任何收益,但如果認股權證以現金行使,則將獲得行使價。註冊允許出售股東不時在公開市場上,通過私下交易或其他方式,以現行市場價格或協議價格出售其股票。Intelligent Bio Solutions Inc.已同意在出售所有註冊股票或以其他方式完成發行之前保持招股說明書的有效性。該公司還與其董事和高級管理人員簽訂了賠償協議,其章程規定在特拉華州法律允許的最大範圍內進行賠償。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息